Navigation Links
Insmed CEO Resigns Due to Health Concerns
Date:6/15/2009

l trial data may take longer than anticipated, competing products may be more successful, the biopharmaceutical industry may experience negative market trends, our continuing efforts to grow the business and develop IPLEX(TM) may be unsuccessful, the actual market for MMD may not actually match up with our external assessment, we may lack financial resources to complete development of product candidates and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2008. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

    Investor Relations Contact:
    Brian Ritchie - FD
    212-850-5683
    brian.ritchie@fd.com

    Media Relations Contact:
    Irma Gomez-Dib - FD
    212-850-5761
    irma.gomez-dib@fd.com


'/>"/>
SOURCE Insmed Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Insmed Announces First Quarter 2009 Financial Results
2. Insmed Regains NASDAQ Compliance
3. Insmed to Host First Quarter 2009 Conference Call
4. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
5. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
6. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
7. Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
8. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
9. Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference
10. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
11. NASDAQs Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmeds Compliance Date to March 20, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... -- Bionomics Limited (ASX:BNO, ADR:BMICY) is to present important ... patients with metastatic renal cancer at the ASCO Genitourinary ... The data will be presented by Dr. Sumanta ... Center in California in his ... Ferritin and IL-8 as two baseline biomarkers that correlate ...
(Date:2/27/2015)... BOSTON , Feb. 27, 2015   PureTech ... identifying, inventing and commercializing disruptive products and technologies in ... Christopher Viehbacher , former CEO and Member of the ... Directors.  "It,s has been a pleasure ... very excited that we will be working together more ...
(Date:2/26/2015)... 2015   Synageva BioPharma Corp. (NASDAQ: ... therapeutic products for rare disorders, today reported 2014 ... other key objectives, and financial guidance.  Synageva,s management ... 4:30 p.m. EST to review the financial results ... in today,s call by telephone, please dial (877) ...
(Date:2/26/2015)... On behalf of biotech client GenScript ... Goldman & Spitzer, P.A. (Wilentz) secured a significant ... Inc. in excess of $10 million. The jury determined ... and that it improperly hired one or more of ... motions for judgment notwithstanding the verdict, a new trial, ...
Breaking Biology Technology:New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... July 30 /PRNewswire-Asia/ -- Eli Lilly & Company ... they have,reached an amicable resolution of all ongoing ... and sale of gemcitabine,hydrochloride around the world. , ... settlement, Lilly has granted ScinoPharm a royalty bearing,license ...
... TOKYO, July 30 With a ... Pharmaceutical Co. Ltd., a subsidiary of,the Zydus group, one of ... looking to give a big boost to its operations,in the ... market in Japan is estimated at $ 60 bn the ...
... viable solar power cellscheap, flexible and easy to makehas ... of recent work* at the National Institute of Standards ... of the complex organic films at the heart of ... molecules to capture sunlight and convert it into electricity, ...
Cached Biology Technology:Eli Lilly & Company and ScinoPharm Taiwan Ltd. Announce Settlement of Gemcitabine Litigation 2"Over the Next 2-3 Years We Will Leverage Developmental Capabilities and Explore In-licensing and a Co-development Model to Consolidate Our Presence in Japan" - Dr. Kailash Sharma, President, Japan Operations, Zydus Cadila 2NIST scientists study how to stack the deck for organic solar power 2
(Date:2/5/2015)... PARK, N.C. , Feb. 5, 2015  Marken ... specialist logistics company and has launched a new marketing ... Clinical Logistics Organization (CLO).  The new campaign focuses on ... on patient, protocol and shipments. The first ... , aligns Marken,s priorities with its client,s priorities. ...
(Date:2/5/2015)... 28, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... Global Online CEO Conference on January 29 th ... Pereira , CEO of NXT-ID will present and host ... Wocket smart wallet and its full suite of biometric ...
(Date:1/22/2015)... Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), ... general the State of Washington,s Department ... new enrollment and central issuance system for driver,s licenses and ... The project planning and development will start in January 2015, ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... the fact that they both infect the liver, the ... little in common. The two are far apart genetically, ... A spreads through the consumption of fecal particles from ... example), but hepatitis C is generally transmitted only by ...
... take concerted action to ensure that people who are at ... according to the authors of a new report published today ... shows that influenza epidemics are associated with a rise in ... the heart attacks that result in death. , However, only ...
... whose brain cells respond to a flash of light are ... and may ultimately yield a better understanding of how the ... and the Howard Hughes Medical Institute have engineered a strain ... light. This was accomplished by inserting into the cells a ...
Cached Biology News:Researchers find hepatitis A and hepatitis C attack same protein to block immune defenses 2New research shows that flu is a trigger of heart attacks 2New research shows that flu is a trigger of heart attacks 3New research shows that flu is a trigger of heart attacks 4Scientists to track impact of Asian dust and pollution on clouds, weather, climate change 2Scientists to track impact of Asian dust and pollution on clouds, weather, climate change 3
... Ligands\n\nReceptor-related research has long been enabled by ... selected to keep pace with new discoveries. ... and services for receptor research and drug ... you do not find exactly what you ...
... UltraPure Agarose and SYBR Safe DNA Gel Stain ... Saves money versus buying these same products separately ... alternative to ethidium bromide ... Agarose resolves DNA and RNA fragments from 100 bp ...
... Odyssey images are easily imported for data analysis , ... ... , Extensive background and signal options to optimize, ... results , ...
... optimized for siRNA applications, contains magnetic nanoparticles ... nucleic acid of interest. Exploiting magnetic force ... rapidly drawn towards and delivered into the ... Reagent can be used for adherent cells; ...
Biology Products: